-
1
-
-
10744221312
-
Infliximab maintenance therapy for fistulizing Crohn?s disease
-
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn?s disease. N Engl J Med 2004; 350:876-885
-
(2004)
N Engl J Med
, vol.350
, pp. 876-885
-
-
Sands, B.E.1
Anderson, F.H.2
Bernstein, C.N.3
Chey, W.Y.4
Feagan, B.G.5
Fedorak, R.N.6
-
2
-
-
0037018761
-
Maintenance infliximab for Crohn?s disease: The ACCENT i randomised trial
-
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al, Maintenance infliximab for Crohn?s disease: the ACCENT I randomised trial, Lancet, 2002, 359, 1541-1549.
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
-
3
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N En gl J Med 2005; 353:2462-2476
-
(2005)
N en Gl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
Reinisch, W.4
Olson, A.5
Johanns, J.6
-
4
-
-
32044451548
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn?s disea se: The CLASSIC-I trial
-
Hanauer SB, SandbornWJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn?s disea se: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
Fedorak, R.N.4
Lukas, M.5
Mac Intosh, D.6
-
5
-
-
84856163835
-
Adalimumab induces and maintains clinical remi ssion in patients with moderate-to-severe ulcerative colitis
-
e1-e3
-
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D?Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remi ssion in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257- 265, e1-e3
-
(2012)
Gastroenterology
, vol.142
, pp. 257-265
-
-
Sandborn, W.J.1
Van Assche, G.2
Reinisch, W.3
Colombel, J.F.4
Dhaens, G.5
Wolf, D.C.6
-
6
-
-
0033529049
-
Infliximab for the treatment of fistulas in patients with Crohn's disease
-
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn? s disease. N Engl J Med 1999; 340:1398-1405
-
(1999)
N Engl J Med
, vol.340
, pp. 1398-1405
-
-
Present, D.H.1
Rutgeerts, P.2
Targan, S.3
Hanauer, S.B.4
Mayer, L.5
Van Hogezand, R.A.6
-
7
-
-
77950988234
-
Infliximab azathioprine or combination therapy for Crohn's disease
-
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn? s disease. N Engl J Med 2010; 362:1383-1395
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
Mantzaris, G.J.4
Kornbluth, A.5
Rachmilewitz, D.6
-
8
-
-
0033842357
-
Use of infliximab in the treatment of Crohn?s disease in children and adolescents
-
Hyams JS, Markowitz J,Wyllie R. Use of infliximab in the treatment of Crohn?s disease in children and adolescents. J Pediatr 2000; 137:192-196
-
(2000)
J Pediatr
, vol.137
, pp. 192-196
-
-
Hyams, J.S.1
Markowitz, J.2
Wyllie, R.3
-
9
-
-
84870293844
-
Ciclosporin versus infliximab in pati ents with severe ulcerative colitis refractory to intravenous steroids: A parallel, open-label randomised controlled trial
-
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in pati ents with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380:1909- 1915
-
(2012)
Lancet
, vol.380
, pp. 1909-1915
-
-
Laharie, D.1
Bourreille, A.2
Branche, J.3
Allez, M.4
Bouhnik, Y.5
Filippi, J.6
-
10
-
-
79959479569
-
Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care
-
Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011; 33:679-707
-
(2011)
Clin Ther
, vol.33
, pp. 679-707
-
-
Curtis, J.R.1
Singh, J.A.2
-
11
-
-
84878536093
-
Development and regulation of biosimilars: Current status and future challenges
-
Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs 2013; 27:203-211
-
(2013)
BioDrugs
, vol.27
, pp. 203-211
-
-
Tsiftsoglou, A.S.1
Ruiz, S.2
Schneider, C.K.3
-
12
-
-
84876938678
-
Biosimilars in IBD: Hope or expectation
-
Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Lö wenberg M, Jairath V, et al. Biosimilars in IBD: hope or expectation Gut 2013; 62:803-807
-
(2013)
Gut
, vol.62
, pp. 803-807
-
-
Gecse, K.B.1
Khanna, R.2
Van Den Brink, G.R.3
Ponsioen, C.Y.4
Lowenberg, M.5
Jairath, V.6
-
13
-
-
0141922918
-
Shifting paradigms: Biopharmaceuticals versus low molecular weight drugs
-
Crommelin DJA, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennink WE. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003; 266:3 -16
-
(2003)
Int J Pharm
, vol.266
, pp. 3-16
-
-
Crommelin, D.J.A.1
Storm, G.2
Verrijk, R.3
De Leede, L.4
Jiskoot, W.5
Hennink, W.E.6
-
14
-
-
84874173298
-
European perspective on biosimilars
-
Wadhwa M, Thorpe R. European perspective on biosimilars. Bioanalysis 2013; 5:521-524
-
(2013)
Bioanalysis
, vol.5
, pp. 521-524
-
-
Wadhwa, M.1
Thorpe, R.2
-
15
-
-
84900410623
-
-
European Medicinal Agency (EMA). Available at Accessed 13 O ctober
-
European Medicinal Agency (EMA). EMA procedural advice for biosimilar applications. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Regulatory-and-procedural-guideline/2009/10/WC500004018.pdf. [Accessed 13 O ctober 2013]
-
(2013)
EMA procedural advice for biosimilar applications
-
-
-
16
-
-
84900416820
-
Title VII-improving access to innovative medical therapies
-
US Food and Drug Administration Available at Accessed 20 November
-
US Food and Drug Administration. Title VII-improving access to innovative medical therapies. ?Biologics Price Competition and Innovation Act of 2009?. Available at: http://www.fda.gov/download s/Drugs/GuidanceCompliance RegulatoryInformation/UCM216146.pdf. [Accessed 20 November 2013]
-
(2013)
?Biologics Price Competition and Innovation Act of 2009?
-
-
-
17
-
-
84900461266
-
-
US Food and Drug Administration Available at Accessed 22 November
-
US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Available at: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf. [Accessed 22 November 2013]
-
(2013)
Scientific Considerations in Demonstrating Biosimilarity to A Reference Product
-
-
-
18
-
-
51349137409
-
Toward biosimilar monoclonal antibodies
-
Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-990
-
(2008)
Nat Biotechnol
, vol.26
, pp. 985-990
-
-
Schneider, C.K.1
Kalinke, U.2
-
19
-
-
84871492817
-
Biosimilars: What clinicians should know
-
Weise M, Bielsky M-C, Smet KD, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood 2012; 120:5111-5117
-
(2012)
Blood
, vol.120
, pp. 5111-5117
-
-
Weise, M.1
Bielsky, M.-C.2
Smet, K.D.3
Ehmann, F.4
Ekman, N.5
Giezen, T.J.6
-
20
-
-
84884910025
-
Review article: Biosimilars are the next generation of drugs for liver and gastrointestinal diseases
-
Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol T her 2013; 38:914-924
-
(2013)
Aliment Pharmacol Ther
, vol.38
, pp. 914-924
-
-
Rinaudo-Gaujous, M.1
Paul, S.2
Tedesco, E.D.3
Genin, C.4
Roblin, X.5
Peyrin-Biroulet, L.6
-
21
-
-
84883880492
-
Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry
-
Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013; 5:621-623
-
(2013)
MAbs
, vol.5
, pp. 621-623
-
-
Beck, A.1
Reichert, J.M.2
-
22
-
-
84883879484
-
Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab
-
Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2 013; 27:495-507
-
(2013)
BioDrugs
, vol.27
, pp. 495-507
-
-
Visser, J.1
Feuerstein, I.2
Stangler, T.3
Schmiederer, T.4
Fritsch, C.5
Schiestl, M.6
-
23
-
-
84860619510
-
Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrels): A double-bli nd, single-dose, crossover study in healthy volunteers
-
Yi S,Kim SE,Park M-K,Yoon SH,Cho J-Y,Lim KS ,et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrels): a double-bli nd, single-dose, crossover study in healthy volunteers, BioDrugs, 2012,26, 177-184.
-
(2012)
BioDrugs
, vol.26
, pp. 177-184
-
-
Yi, S.1
Kim, S.E.2
Park, M.-K.3
Yoon, S.H.4
Cho, J.-Y.5
Lim, K.S.6
-
24
-
-
83455201580
-
Comparative pharmacokinetics and tolerabi lity of branded etanercept (25 mg) and its biosimilar (25 mg): A randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers
-
Gu N, Yi S, Kim T-E, Kim J, Shin S-G, Jang I-J, et al. Comparative pharmacokinetics and tolerabi lity of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 2011; 33:2029-2037
-
(2011)
Clin Ther
, vol.33
, pp. 2029-2037
-
-
Gu, N.1
Yi, S.2
Kim, T.-E.3
Kim, J.4
Shin, S.-G.5
Jang, I.-J.6
-
25
-
-
84900436651
-
-
Available at Accessed 5 March
-
Merck. 2013 Mer ck annual report. Available at: http://www.merck.com/ investors/financials/annual-reports/. [Accessed 5 March 2014]
-
(2014)
Merck. 2013 Merck Annual Report
-
-
-
26
-
-
70450195261
-
Controlling the cost of innovative cancer therapeutics
-
Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009; 6:550-552
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 550-552
-
-
Malik, N.N.1
-
27
-
-
84861842454
-
Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry
-
Beck A, Sanglier-Cianfé rani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-4646
-
(2012)
Anal Chem
, vol.84
, pp. 4637-4646
-
-
Beck, A.1
Sanglier-Cianferani, S.2
Van Dorsselaer, A.3
-
28
-
-
62949147825
-
-
EMA statement on Inflectra Available at Accessed 13 October
-
European Medicinal Agency (EMA). EMA statement on Inflectra. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion- Initial-authorisation/human/002778/WC500144831.pdf. [Accessed 13 October 2013]
-
(2013)
European Medicinal Agency (EMA)
-
-
-
29
-
-
0015791561
-
Human-mouse somatic cell hybrid clone secreting immunoglobulins of both parental types
-
Schwaber J, Cohen EP. Human-mouse somatic cell hybrid clone secreting immunoglobulins of both parental types. Nature 1973; 244:444-447
-
(1973)
Nature
, vol.244
, pp. 444-447
-
-
Schwaber, J.1
Cohen, E.P.2
-
30
-
-
84883752718
-
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in pa tients with active rheumatoid arthritis: The PLANETRA study
-
Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in pa tients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613-1620
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1613-1620
-
-
Yoo, D.H.1
Hrycaj, P.2
Miranda, P.3
Ramiterre, E.4
Piotrowski, M.5
Shevchuk, S.6
-
31
-
-
84883746909
-
A randomised, dou ble-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study
-
Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, dou ble-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72:160 5-1612
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1605-1612
-
-
Park, W.1
Hrycaj, P.2
Jeka, S.3
Kovalenko, V.4
Lysenko, G.5
Miranda, P.6
-
32
-
-
84875477617
-
The continuum of comparability extends to biosimilarity: How much is enough and what clinical data are necessary
-
McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary Clin Pharmacol Ther 2013; 93:315-317
-
(2013)
Clin Pharmacol Ther
, vol.93
, pp. 315-317
-
-
Mc Camish, M.1
Woollett, G.2
-
34
-
-
84870933584
-
Interchangeability, immunogenicity and biosimilars
-
Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30:1186-1190
-
(2012)
Nat Biotechnol
, vol.30
, pp. 1186-1190
-
-
Ebbers, H.C.1
Crow, S.A.2
Vulto, A.G.3
Schellekens, H.4
-
35
-
-
84870935790
-
Setting the stage for biosimilar monoclonal a ntibodies
-
Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin J-H, Weise M, et al. Setting the stage for biosimilar monoclonal a ntibodies. Nat Biotechnol 2012; 30:1179-1185
-
(2012)
Nat Biotechnol
, vol.30
, pp. 1179-1185
-
-
Schneider, C.K.1
Vleminckx, C.2
Gravanis, I.3
Ehmann, F.4
Trouvin, J.-H.5
Weise, M.6
-
36
-
-
79953861167
-
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
-
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceutica ls. Nat Biotechnol 2011; 29:310-312
-
(2011)
Nat Biotechnol
, vol.29
, pp. 310-312
-
-
Schiestl, M.1
Stangler, T.2
Torella, C.3
Cepeljnik, T.4
Toll, H.5
Grau, R.6
-
37
-
-
33748921915
-
Biophysical comparability of the same protein from different manufacturers: A case study using epoetin alfa fr om Epogen and Eprex
-
Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using epoetin alfa fr om Epogen and Eprex. J Pharm Sci 2006; 95:1931-1943
-
(2006)
J Pharm Sci
, vol.95
, pp. 1931-1943
-
-
Deechongkit, S.1
Aoki, K.H.2
Park, S.S.3
Kerwin, B.A.4
-
38
-
-
84884901120
-
Epoetin biosimilars in Europe: Five years on
-
Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther 2013; 30:28-40
-
(2013)
Adv Ther
, vol.30
, pp. 28-40
-
-
Mikhail, A.1
Farouk, M.2
-
39
-
-
79953154625
-
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: A randomized prospective study
-
Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs R D 2011; 11:61-7 5
-
(2011)
Drugs RD
, vol.11
, pp. 61-75
-
-
Lissy, M.1
Ode, M.2
Roth, K.3
-
40
-
-
41149131276
-
Epoetin zeta study group comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia tr eatment
-
Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia tr eatment. Curr Med Res Opin 2008; 24:625-637
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 625-637
-
-
Wizemann, V.1
Rutkowski, B.2
Baldamus, C.3
Scigalla, P.4
Koytchev, R.5
-
41
-
-
69949150756
-
Long-term safety and tolerability of epoetin zeta, administered in travenously, for maintenance treatment of renal anemia
-
Baldamus C, Krivoshiev S,Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered in travenously, for maintenance treatment of renal anemia. Adv Ther 2008; 25:1215-1228
-
(2008)
Adv Ther
, vol.25
, pp. 1215-1228
-
-
Baldamus, C.1
Krivoshiev, S.2
Wolf-Pflugmann, M.3
Siebert-Weigel, M.4
Koytchev, R.5
Bronn, A.6
-
42
-
-
44349139462
-
Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia
-
Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008; 24:1407-1415
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 1407-1415
-
-
Krivoshiev, S.1
Todorov, V.V.2
Manitius, J.3
Czekalski, S.4
Scigalla, P.5
Koytchev, R.6
-
43
-
-
79251633136
-
Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis
-
Wiecek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther 2010; 27:941-952
-
(2010)
Adv Ther
, vol.27
, pp. 941-952
-
-
Wiecek, A.1
Ahmed, I.2
Scigalla, P.3
Koytchev, R.4
-
44
-
-
79952488808
-
Quality of original and biosimilar epoetin products
-
Brinks V, Hawe A, Basmeleh AHH, Joachin-Rodriguez L, Haselberg R, Somsen GW, et al. Quality of original and biosimilar epoetin products. Pharm Res 2011; 28:38 6-393
-
(2011)
Pharm Res
, vol.28
, pp. 386-393
-
-
Brinks, V.1
Hawe, A.2
Basmeleh, A.H.H.3
Joachin-Rodriguez, L.4
Haselberg, R.5
Somsen, G.W.6
-
45
-
-
78650543555
-
Impact of product-related factors on immunogenicity of biotherapeutics
-
Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011; 100:354-387
-
(2011)
J Pharm Sci
, vol.100
, pp. 354-387
-
-
Singh, S.K.1
-
46
-
-
84884283941
-
Clinical experience with Zarzios in Europe: What have we learned
-
Gascó n P, Tesch H, Verpoort K, Rosati MS, Salesi N, Agrawal S, et al. Clinical experience with Zarzios in Europe: what have we learned Support Care Cancer 2013; 21:2925-2932
-
(2013)
Support Care Cancer
, vol.21
, pp. 2925-2932
-
-
Gascon, P.1
Tesch, H.2
Verpoort, K.3
Rosati, M.S.4
Salesi, N.5
Agrawal, S.6
-
47
-
-
78650515906
-
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
-
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47:8-32
-
(2011)
Eur J Cancer
, vol.47
, pp. 8-32
-
-
Aapro, M.S.1
Bohlius, J.2
Cameron, D.A.3
Dal Lago, L.4
Donnelly, J.P.5
Kearney, N.6
-
49
-
-
77954653769
-
Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator
-
Jiang H,Wu S-L, Karger BL, H ancock WS. Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal Chem 2010; 82:6154-6162
-
(2010)
Anal Chem
, vol.82
, pp. 6154-6162
-
-
Jiang Hwu, S.-L.1
Karger, B.L.2
Hancock, W.S.3
-
50
-
-
47549097069
-
Epoetin-associated pure red cell aplasia: Past, present, and future considerations
-
McKoy JM, Stonecas h RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48:1754-1762
-
(2008)
Transfusion
, vol.48
, pp. 1754-1762
-
-
McKoy, J.M.1
Stonecas, H.R.E.2
Cournoyer, D.3
Rossert, J.4
Nissenson, A.R.5
Raisch, D.W.6
-
51
-
-
19044397056
-
Epoetinassociated pure red cell aplasia in patients with chronic kidney disease: Solving the mystery
-
Boven K, Knight J, Bader F, Rossert J, Eckardt K-U, Casadevall N. Epoetinassociated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005; 20 (Suppl 3):iii33-iii40
-
(2005)
Nephrol Dial Transplant
, vol.20
, Issue.SUPPL.3
-
-
Boven, K.1
Knight, J.2
Bader, F.3
Rossert, J.4
Eckardt, K.-U.5
Casadevall, N.6
-
52
-
-
77957723026
-
Biosimilar epoetins and other 'follow-on' biologics: Update on the European experiences
-
Jelkmann W. Biosimilar epoetins and other ?follow-on? biologics: update on the European experiences. Am J Hematol 2010; 85:771-780
-
(2010)
Am J Hematol
, vol.85
, pp. 771-780
-
-
Jelkmann, W.1
-
53
-
-
84862644490
-
Tungsteninduced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity
-
Seidl A, Hainzl O, Richter M, Fischer R, Bö hm S, Deutel B, et al. Tungsteninduced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2012; 29:1454-1467
-
(2012)
Pharm Res
, vol.29
, pp. 1454-1467
-
-
Seidl, A.1
Hainzl, O.2
Richter, M.3
Fischer, R.4
Bohm, S.5
Deutel, B.6
-
54
-
-
79958824101
-
Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies
-
Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80:88-92
-
(2011)
Kidney Int
, vol.80
, pp. 88-92
-
-
Praditpornsilpa, K.1
Tiranathanagul, K.2
Kupatawintu, P.3
Jootar, S.4
Intragumtornchai, T.5
Tungsanga, K.6
-
55
-
-
84885871577
-
Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: Interim results of a postauthorizatio n safety study
-
Becker P, Brauninger S, Bialleck H. Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: interim results of a postauthorizatio n safety study. Bone Marrow Transplant 2013; 48:O177
-
(2013)
Bone Marrow Transplant
, vol.48
-
-
Becker, P.1
Brauninger, S.2
Bialleck, H.3
-
56
-
-
84878624235
-
Governing Board and Operational Board of ECCO. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
-
Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7:586-589
-
(2013)
J Crohns Colitis
, vol.7
, pp. 586-589
-
-
Danese, S.1
Gomollon, F.2
-
57
-
-
84878532312
-
Joint position statement by Spanish Society of gastroenterology and spanish society of pharmacology on biosimilar therapy for inflamm atory bowel disease
-
Argü elles-Arias F, Barreiro-de-Acosta M, Carballo F, Hinojosa J, Tejerina T. Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflamm atory bowel disease. Rev Esp Enferm Dig 2013; 105:37-43
-
(2013)
Rev Esp Enferm Dig
, vol.105
, pp. 37-43
-
-
Arguelles-Arias, F.1
Barreiro-De-Acosta, M.2
Carballo, F.3
Hinojosa, J.4
Tejerina, T.5
-
58
-
-
0034754477
-
Etanercept for active Crohn?s disease: A randomized, double -blind, placebocontrolled trial
-
Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn?s disease: a randomized, double -blind, placebocontrolled trial. Gastroenterology 2001; 121:1088-1094
-
(2001)
Gastroenterology
, vol.121
, pp. 1088-1094
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Katz, S.3
Safdi, M.4
Wolf, D.G.5
Baerg, R.D.6
-
59
-
-
84862741536
-
Abatacept for Crohn?s disease an d ulcerative colitis
-
e4
-
Sandborn WJ, Colombel J-F, Sands BE, Rutgeerts P, Targan SR, Panaccione R, et al. Abatacept for Crohn?s disease an d ulcerative colitis. Gastroenterology 2012; 143:62- 69, e4
-
(2012)
Gastroenterology
, vol.143
, pp. 62-69
-
-
Sandborn, W.J.1
Colombel, J.-F.2
Sands, B.E.3
Rutgeerts, P.4
Targan, S.R.5
Panaccione, R.6
|